78764 Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 

1 89 FR 407. 

2Adjustment to the Aggregate Production Quota 

for Lisdexamfetamine and d-Amphetamine (for 

Conversion) for 2024, 89 FR 72424 (Sept. 5, 2024). 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1228A] 

Proposed Adjustments to the 

Aggregate Production Quotas for 

Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2024 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration proposes to adjust the 

2024 aggregate production quotas for 

several controlled substances in 

schedules I and II of the Controlled 

Substances Act. Additionally, as DEA 

announced in an April 29, 2024 letter to 

DEA-registered manufacturers, 

procurement quotas for commercial 

manufacturing of a schedule II 

controlled substance will be calculated 

on a semi-annual basis, except for 

injectable drug products containing 

schedule II controlled substances, 

which will be calculated on an annual 

basis. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.13(c) and 

1315.13(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before 

October 25, 2024. Commenters should 

be aware that the electronic Federal 

Docket Management System will not 

accept comments after 11:59 p.m. 

Eastern Time on the last day of the 

comment period. 

Based on comments received in 

response to this notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

her sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the 

Administrator will publish in the 

Federal Register a final order 

establishing the 2024 adjusted aggregate 

production quotas for schedule I and II 

controlled substances, and an adjusted 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, as relevant. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–1228A’’ on all 

correspondence, including any 

attachments. DEA encourages that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to http:// 

www.regulations.gov and follow the 

online instructions at that site for 

submitting comments. Upon completion 

of your submission, you will receive a 

Comment Tracking Number for your 

comment. Please be aware that 

submitted comments are not 

instantaneously available for public 

view on Regulations.gov. If you have 

received a Comment Tracking Number, 

your comment has been successfully 

submitted and there is no need to 

resubmit the same comment. Paper 

comments that duplicate electronic 

submissions are not necessary and are 

discouraged. Should you wish to mail a 

paper comment in lieu of an electronic 

comment, it should be sent via regular 

or express mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Heather E. Achbach, Regulatory Drafting 

and Policy Support Section, Diversion 

Control Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: 571–776–3882. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received in response to this docket are 

considered part of the public record. 

They will, unless reasonable cause is 

given, be made available by the Drug 

Enforcement Administration (DEA) for 

public inspection online at http://

www.regulations.gov. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

The Freedom of Information Act 

applies to all comments received. If you 

want to submit personal identifying 

information (such as your name, 

address, etc.) as part of your comment, 

but do not want it to be made publicly 

available, you must include the phrase 

‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want made publicly 

available in the first paragraph of your 

comment and identify what information 

you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. 

Comments containing personal 

identifying information or confidential 

business information identified and 

located as directed above will generally 

be made available in redacted form. If a 

comment contains so much confidential 

business information or personal 

identifying information that it cannot be 

effectively redacted, all or part of that 

comment may not be made publicly 

available. Comments posted to http://

www.regulations.gov may include any 

personal identifying information (such 

as name, address, and phone number) 

included in the text of your electronic 

submission that is not identified as 

directed above as confidential. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

Legal Authority and Background 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

(APQ) for each basic class of controlled 

substance listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. The Attorney 

General has delegated this function to 

the Administrator of DEA pursuant to 

28 CFR 0.100. 

DEA established the 2024 APQ for 

substances in schedules I and II and the 

assessment of annual needs (AAN) for 

the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine on January 3, 

2024.1 That order stipulated that, in 

accordance with 21 CFR 1303.13 and 

1315.13, all APQ and AAN are subject 

to adjustment. DEA published a Final 

Order revising the 2024 

lisdexamfetamine and d-amphetamine 

(for conversion) APQ on September 5, 

2024.2


ddrumheller on DSK120RN23PROD with NOTICES7
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 78765 

3 21 CFR 1303.13(a), 1315.13(a). 

4 74 FR 60294 (Nov. 20, 2009); 75 FR 79407 (Dec. 

20, 2010). 

5 74 FR 60294 (Nov. 20, 2009); 75 FR 79407 (Dec. 

20, 2010). 

6 21 U.S.C. 826(i)(1)(A). 

7 21 U.S.C. 826(i)(1). 

8All functions vested in the Attorney General by 

the CSA have been delegated to the Administrator 

of DEA. 28 CFR 0.100(b); 21 U.S.C. 826(i)(1)(C). 

9 21 U.S.C. 826(i)(1)(B). 

Analysis for Proposed Adjusted 2024 

Aggregate Production Quotas and 

Assessment of Annual Needs 

DEA proposes to adjust the 

established 2024 APQ for certain 

schedule I and II controlled substances 

and the AAN for certain list I chemicals 

to be manufactured in the United States 

in 2024 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

lawful export requirements, and for the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. 

Factors for Determining the Proposed 

Adjustments 

In determining the proposed 

adjustments, the Administrator has 

taken into account the factors in 21 CFR 

1303.13 (adjustment of APQ for 

controlled substances) and 21 CFR 

1315.13 (adjustment of the AAN for 

ephedrine, pseudoephedrine, and 

phenylpropanolamine). The 

Administrator is authorized to increase 

or reduce the APQ and the AAN at any 

time.3

DEA determined whether to propose 

an adjustment of the APQ for 2024 by 

considering the factors found at 21 CFR 

1303.13(b): 

(1) Changes in the demand for that class, 

changes in the national rate of net disposal 

of the class, changes in the rate of net 

disposal of the class by registrants holding 

individual manufacturing quotas for that 

class, and changes in the extent of any 

diversion in the class; 

(2) Whether any increased demand for that 

class, the national and/or individual rates of 

net disposal of that class are temporary, short 

term, or long term; 

(3) Whether any increased demand for that 

class can be met through existing inventories, 

increased individual manufacturing quotas, 

or increased importation, without increasing 

the aggregate production quota, taking into 

account production delays and the 

probability that other individual 

manufacturing quotas may be suspended 

pursuant to [21 CFR] 1303.24(b); 

(4) Whether any decreased demand for that 

class will result in excessive inventory 

accumulation by all persons registered to 

handle that class (including manufacturers, 

distributors, practitioners, importers, and 

exporters), notwithstanding the possibility 

that individual manufacturing quotas may be 

suspended pursuant to [21 CFR] 1303.24(b) 

or abandoned pursuant to [21 CFR] 1303.27; 

(5) Other factors affecting medical, 

scientific, research, and industrial needs in 

the United States and lawful export 

requirements, as the Administrator finds 

relevant, including changes in the currently 

accepted medical use in treatment with the 

class or the substances which are 

manufactured from it, the economic and 

physical availability of raw materials for use 

in manufacturing and for inventory purposes, 

yield and stability problems, potential 

disruptions to production (including possible 

labor strikes), and recent unforeseen 

emergencies such as floods and fires. 

DEA also considered updated 

information obtained from 2023 yearend inventories, 2023 disposition data 

submitted by quota applicants, changes 

in estimates of the medical needs of the 

United States, export requirements, and 

other information made available to 

DEA after the initial APQ and AAN had 

been established. Additional factors the 

Administrator considered in calculating 

the APQ, but not the AAN, include 

product development requirements of 

both bulk and finished dosage form 

manufacturers. 

After considering the changes in the 

extent of diversion of all controlled 

substances, as required by 21 CFR 

1303.13(b)(1), DEA has determined that 

any changes from the initial calculations 

are slight and not statistically significant 

from the estimates of diversion that DEA 

applied to the initial APQ valuations. 

DEA determined whether to propose 

an adjustment of the AAN for 2024 by 

considering the factors found at 21 CFR 

1315.13(b) and summarized below: 

(1) Changes in the demand for that 

chemical, changes in the national rate of net 

disposal of the chemical, and changes in the 

rate of net disposal of the chemical by 

registrants holding individual manufacturing 

or import quotas for that chemical; 

(2) Whether any increased demand for that 

chemical, the national and/or changes in 

individual rates of net disposal of that 

chemical are temporary, short term, or long 

term; 

(3) Whether any increased demand for that 

chemical can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 

importation, without increasing the 

assessment of annual needs, taking into 

account production delays and the 

probability that other individual 

manufacturing quotas may be suspended 

pursuant to [21 CFR] 1315.24(b); 

(4) Whether any decreased demand for that 

chemical will result in excessive inventory 

accumulation by all persons registered to 

handle that chemical (including 

manufacturers, distributors, importers, and 

exporters), notwithstanding the possibility 

that individual manufacturing quotas may be 

suspended pursuant to [21 CFR] 1315.24(b) 

or abandoned pursuant to [21 CFR] 1315.27; 

(5) Other factors affecting medical, 

scientific, research, industrial, and 

importation needs in the United States, 

lawful export requirements, and reserve 

stocks, as the Administrator finds relevant, 

including changes in the currently accepted 

medical use in treatment with the chemical 

or the substances that are manufactured from 

it, the economic and physical availability of 

raw materials for use in manufacturing and 

for inventory purposes, yield and stability 

problems, potential disruptions to 

production (including possible labor strikes), 

and recent unforeseen emergencies such as 

floods and fires. 

In evaluating whether there is a need 

for adjustment of the 2024 AAN for list 

I chemicals, DEA used the calculation 

methodology previously described in 

the 2010 and 2011 AAN.4 DEA 

considered the total net disposals of the 

list I chemicals for the current and 

preceding two years, actual and 

estimated inventories, projected 

demand, industrial use, and export 

requirements from data provided by 

DEA registered manufacturers and 

importers on the relevant quota 

application forms.5

Additional Considerations Applicable to 

Covered Controlled Substances 

When setting APQ, the Administrator 

must estimate the amount of diversion 

of any substance that is considered a 

‘‘covered controlled substance.’’ 6 The 

covered controlled substances are 

fentanyl, oxycodone, hydrocodone, 

oxymorphone, and hydromorphone.7

DEA is required to ‘‘make appropriate 

quota reductions, as determined by the 

[Administrator], from the quota the 

[Administrator] would have otherwise 

established had such diversion not been 

considered.’’ 8 When estimating 

diversion, the Administrator ‘‘shall 

consider information’’ that she, in 

consultation with the Secretary of 

Health and Human Services, 

‘‘determines reliable on rates of 

overdose deaths and abuse and overall 

public health impact related to the 

covered controlled substance in the 

United States;’’ and ‘‘may take into 

consideration’’ whatever other sources 

of information she determines reliable.9

DEA sent letters to the Centers for 

Disease Control and Prevention (CDC), 

the Food and Drug Administration 

(FDA), and the states in March, April, 

and May 2024 requesting overdose 

death and overprescribing data that 

could be considered in estimating 

diversion. DEA received information 

from the CDC in May 2024, the FDA in 

June 2024, and has begun receiving 

Prescription Data Monitoring Program 


ddrumheller on DSK120RN23PROD with NOTICES7
78766 Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 

10 88 FR 75312 (November 2, 2023). 

11https://www.whitehouse.gov/briefing-room/ 

statements-releases/2024/03/13/fact-sheet-bidenharris-administration-launches-the-white-housechallenge-to-save-lives-from-overdose/. 

12https://www.fda.gov/news-events/pressannouncements/fda-approves-second-over-counternaloxone-nasal-spray-product. 

13 89 FR 407. 

14 89 FR 18793 (March, 15, 2024). 

(PDMP) data from the states. DEA 

considered this information in 

developing the estimates of diversion 

for the five covered controlled 

substances for this proposed 

adjustment. 

DEA also aggregated data for each 

covered controlled substance from Drug 

Theft and Loss Reports to determine the 

estimates of diversion. DEA gathered 

data involving employee theft, breakins, armed robberies, and material lost 

in transit. DEA calculated the metric 

weight in grams of each active 

pharmaceutical ingredient (API) of the 

controlled substances being diverted as 

identified in these reports. In 

calculating the estimates of diversion, 

DEA utilized the same methodology as 

published in the Proposed Aggregate 

Production Quotas for Schedule I and II 

Controlled Substances and Assessment 

of Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2024.10

Below, DEA provides an updated chart 

showing estimations of diversion for 

each of the covered controlled 

substances. 

DIVERSION ESTIMATES FOR 2024 (g) 

Fentanyl ........................................ 112 

Hydrocodone ................................ 124,170 

Hydromorphone ............................ 1,137 

Oxycodone .................................... 263,236 

Oxymorphone ............................... 165 

Implementation of Semi-Annual Quota 

Allotment 

For the 2024 quota year, DEA 

announced that it intended to allocate 

procurement quotas to DEA-registered 

manufacturers of schedule II controlled 

substances on a quarterly basis, in order 

to help DEA prevent shortages and be 

more nimble in its administration of the 

quota program. After the announcement, 

DEA met with several manufacturers to 

discuss the impact of that change. 

Numerous manufacturers asked DEA to 

consider allocating quotas semiannually to assist with production 

planning and execution. DEA 

understands and appreciates the 

complexities of the supply chain. In 

light of the discussions with 

manufacturers, as well as meetings with 

FDA discussing their statutory 

obligations for drug availability to meet 

legitimate patients’ needs, input from 

health associations in foreign countries, 

and consideration of the continuing 

issues with the supply chain in the 

aftermath of the COVID–19 pandemic, 

DEA determined that it would and will 

allocate procurement quotas for 

schedule II controlled substances on a 

semi-annual basis, except that it would 

and will allocate procurement quotas for 

injectable drug products containing 

schedule II controlled substances on an 

annual basis. DEA announced this 

change in a letter to DEA-registered 

manufacturers on April 29, 2024. No 

further change is being implemented at 

this time. DEA remains committed to 

ensuring that all patients with legitimate 

medical need can access appropriately 

prescribed medications that are 

manufactured domestically. 

Proposed Adjustments for the 2024 

Aggregate Production Quotas and 

Assessment of Annual Needs 

DEA is proposing increases to the 

APQ for the following schedule I 

substances: psilocybin and psilocyn. 

These proposed increases are to support 

research and clinical trials by DEAregistered schedule I researchers. These 

proposed increases demonstrate DEA’s 

support for research with schedule I 

controlled substances. The proposed 

increases reflect research and 

development needs as part of the 

process for seeking the FDA approval of 

new drug products. 

DEA is proposing increases to the 

APQ for the following schedule II 

substances: noroxymorphone (for 

conversion), oripavine, and 

oxymorphone (for conversion). These 

proposed increases are necessary to 

meet manufacturing needs and 

increased consumption of naloxone 

products as standard treatment for 

opioid overdose. These substances are 

part of the synthesis pathway to 

manufacture naloxone products. On 

March 13, 2024, the ‘‘White House 

Challenge to Save Lives from Overdose’’ 

was announced in support of the 

Administration’s Unity Agenda efforts 

to address the opioid overdose crisis.11

The challenge is a nationwide initiative 

to increase training, awareness, and 

access to lifesaving opioid overdose 

reversal medications. The FDA has 

approved two over the counter (OTC) 

naloxone products for the emergency 

treatment of opioid overdose.12 As a 

result of the White House Challenge and 

efforts by the Department of Health and 

Human Services to help recipients of 

State and Tribal Opioid Response 

Grants increase distribution of opioid 

overdose reversal agents, DEA is 

expecting medical usage of naloxone to 

continue to rise in 2024. The proposed 

increase to the APQ of noroxymorphone 

(for conversion), oripavine and 

oxymorphone (for conversion) reflects 

this increasing medical usage of 

naloxone. 

DEA is proposing decreases to the 

following APQ: fentanyl, hydrocodone 

(for sale), hydromorphone, and 

oxycodone (for sale). These proposed 

decreases are based on adjustments to 

the diversion estimates for calendar year 

2024. 

DEA established the 2024 APQ for 

substances in schedules I and II on 

January 3, 2024.13 Subsequent to that 

publication, DEA published in the 

Federal Register a final rule to 

permanently schedule 2-methyl AP-237 

under the CSA.14 As a result, this 

substance is subject to CSA schedule I 

controls and DEA is proposing to assign 

an individual APQ for this substance 

pursuant to 21 U.S.C. 826 and 21 CFR 

part 1303. 

The Administrator, therefore, 

proposes to adjust the 2024 APQ for the 

schedule I and II controlled substances 

noroxymorphone (for conversion), 

oripavine, oxymorphone (for 

conversion), psilocybin, psilocyn, and 

2-methyl AP–237. The proposed 

adjusted APQ and AAN, as expressed in 

grams of anhydrous acid or base, are as 

follows: 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

New Temporary Controlled Schedule I Substances 

4F-MDMB-BUTICA .................................................................................................................................................. 30 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 78767 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

5F-EDMB-PICA ........................................................................................................................................................ 30 no change 

ADB-4en-PINACA .................................................................................................................................................... 30 no change 

Clonazolam .............................................................................................................................................................. 30 no change 

CUMYL-PEGACLONE ............................................................................................................................................. 30 no change 

Diclazepam .............................................................................................................................................................. 30 no change 

Etizolam ................................................................................................................................................................... 30 no change 

Flualprazolam .......................................................................................................................................................... 30 no change 

Flubromazolam ........................................................................................................................................................ 30 no change 

MDMB-4en-PINACA ................................................................................................................................................ 30 no change 

MMB-FUBICA .......................................................................................................................................................... 30 no change 

Schedule I 

-[1-(2-Thienyl)cyclohexyl]pyrrolidine ........................................................................................................................ 20 no change 

1-(1-Phenylcyclohexyl)pyrrolidine ............................................................................................................................ 30 no change 

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine ...................................................................................................... 10 no change 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ................................................................................................ 30 no change 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ............................................................................................... 30 no change 

1-[1-(2-Thienyl)cyclohexyl]piperidine ....................................................................................................................... 15 no change 

2′-fluoro 2-fluorofentanyl .......................................................................................................................................... 30 no change 

1-Benzylpiperazine .................................................................................................................................................. 25 no change 

1-Methyl-4-phenyl-4-propionoxypiperidine ............................................................................................................... 10 no change 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ............................................................................................... 30 no change 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ............................................................................................ 30 no change 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .............................................................................................. 30 no change 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) .......................................................................................... 30 no change 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ........................................................................................................... 100 no change 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi36) ........................................................................................................................................................................ 30 no change 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ............................................................................................ 30 no change 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi82) ........................................................................................................................................................................ 25 no change 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) .................................................................................................. 30 no change 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ...... 30 no change 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .......................................................................................................... 25 no change 

2,5-Dimethoxy-4-n-propylthiophenethylamine ......................................................................................................... 25 no change 

2,5-Dimethoxyamphetamine .................................................................................................................................... 25 no change 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) .................................................................................... 30 no change 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .............................................................................. 30 no change 

2-Methyl AP-237 ...................................................................................................................................................... 0 30 

3,4,5-Trimethoxyamphetamine ................................................................................................................................ 30 no change 

3,4-Methylenedioxyamphetamine (MDA) ................................................................................................................ 12,000 no change 

3,4-Methylenedioxymethamphetamine (MDMA) ..................................................................................................... 12,000 no change 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................................. 40 no change 

3,4-Methylenedioxy-N-methylcathinone (methylone) .............................................................................................. 5,200 no change 

3,4-Methylenedioxypyrovalerone (MDPV) ............................................................................................................... 35 no change 

3-FMC; 3-Fluoro-N-methylcathinone ....................................................................................................................... 25 no change 

3-Methylfentanyl ....................................................................................................................................................... 30 no change 

3-Methylmethcathinone ............................................................................................................................................ 30 no change 

3-Methylthiofentanyl ................................................................................................................................................. 30 no change 

4,4′-Dimethylaminorex ............................................................................................................................................. 30 no change 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .......................................................................................................... 30 no change 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ...................................................................................................... 5,100 no change 

4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP) ............................................................................. 25 no change 

4-CN-Cumyl-Butinaca .............................................................................................................................................. 25 no change 

4-Fluoroisobutyryl fentanyl ....................................................................................................................................... 30 no change 

4F-MDMB-BINACA .................................................................................................................................................. 30 no change 

4-FMC; Flephedrone ................................................................................................................................................ 25 no change 

4-MEC; 4-Methyl-N-ethylcathinone .......................................................................................................................... 25 no change 

4-Methoxyamphetamine .......................................................................................................................................... 150 no change 

4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (alpha-PiHP) ............................................................................. 30 no change 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .......................................................................................................... 25 no change 

4-Methylaminorex .................................................................................................................................................... 25 no change 

4-Methyl-N-methylcathinone (mephedrone) ............................................................................................................ 45 no change 

4-Methyl-alpha-ethylaminopentiophenone (4-MEAP) .............................................................................................. 25 no change 

4-Methyl-alpha-pyrrolidinohexiophenone (MPHP) ................................................................................................... 25 no change 

4′-Methyl acetyl fentanyl .......................................................................................................................................... 30 no change 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ................................................................................................... 25 no change 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ............................................................................. 50 no change 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40 no change 

5F-AB-PINACA; (1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ................... 25 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
78768 Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 25 no change 

5F-CUMYL-P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide ........... 25 no change 

5F-CUMYL-PINACA ................................................................................................................................................ 25 no change 

5F-EDMB-PINACA ................................................................................................................................................... 25 no change 

5F-MDMB-PICA ....................................................................................................................................................... 25 no change 

5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ....................................... 25 no change 

5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ............................ 25 no change 

5-Fluoro-PB-22; 5F-PB-22 ....................................................................................................................................... 25 no change 

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................ 25 no change 

5-Methoxy-3,4-methylenedioxyamphetamine .......................................................................................................... 25 no change 

5-Methoxy-N,N-diisopropyltryptamine ...................................................................................................................... 25 no change 

5-Methoxy-N,N-dimethyltryptamine ......................................................................................................................... 11,000 no change 

AB-CHMINACA ........................................................................................................................................................ 30 no change 

AB-FUBINACA ......................................................................................................................................................... 50 no change 

AB-PINACA .............................................................................................................................................................. 30 no change 

ADB-BUTINACA ...................................................................................................................................................... 30 no change 

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ...... 30 no change 

Acetorphine .............................................................................................................................................................. 25 no change 

Acetyl Fentanyl ........................................................................................................................................................ 100 no change 

Acetyl-alpha-methylfentanyl ..................................................................................................................................... 30 no change 

Acetyldihydrocodeine ............................................................................................................................................... 30 no change 

Acetylmethadol ........................................................................................................................................................ 25 no change 

Acryl Fentanyl .......................................................................................................................................................... 25 no change 

ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .......................... 50 no change 

AH-7921 ................................................................................................................................................................... 30 no change 

All other tetrahydrocannabinol ................................................................................................................................. 1,166,130 no change 

Allylprodine .............................................................................................................................................................. 25 no change 

Alphacetylmethadol .................................................................................................................................................. 25 no change 

alpha-Ethyltryptamine .............................................................................................................................................. 25 no change 

Alphameprodine ....................................................................................................................................................... 25 no change 

Alphamethadol ......................................................................................................................................................... 25 no change 

alpha-Methylfentanyl ................................................................................................................................................ 30 no change 

alpha-Methylthiofentanyl .......................................................................................................................................... 30 no change 

alpha-Methyltryptamine (AMT) ................................................................................................................................ 25 no change 

alpha-Pyrrolidinobutiophenone (a-PBP) .................................................................................................................. 25 no change 

alpha-pyrrolidinoheptaphenone (PV8) ..................................................................................................................... 25 no change 

alpha-pyrrolidinohexabophenone (alpha-PHP) ........................................................................................................ 25 no change 

alpha-Pyrrolidinopentiophenone (a-PVP) ................................................................................................................ 25 no change 

Amineptine ............................................................................................................................................................... 30 no change 

Aminorex .................................................................................................................................................................. 25 no change 

Anileridine ................................................................................................................................................................ 20 no change 

APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ............................................................. 25 no change 

Benzethidine ............................................................................................................................................................ 25 no change 

Benzylmorphine ....................................................................................................................................................... 30 no change 

Betacetylmethadol ................................................................................................................................................... 25 no change 

beta-Hydroxy-3-methylfentanyl ................................................................................................................................ 30 no change 

beta-Hydroxyfentanyl ............................................................................................................................................... 30 no change 

beta-Hydroxythiofentanyl ......................................................................................................................................... 30 no change 

beta-Methyl fentanyl ................................................................................................................................................ 30 no change 

beta′-Phenyl fentanyl ............................................................................................................................................... 30 no change 

Betameprodine ......................................................................................................................................................... 25 no change 

Betamethadol ........................................................................................................................................................... 4 no change 

Betaprodine .............................................................................................................................................................. 25 no change 

Brorphine ................................................................................................................................................................. 30 no change 

Bufotenine ................................................................................................................................................................ 15 no change 

Butonitazene ............................................................................................................................................................ 30 no change 

Butylone ................................................................................................................................................................... 25 no change 

Butyryl fentanyl ........................................................................................................................................................ 30 no change 

Cathinone ................................................................................................................................................................. 40 no change 

Clonitazene .............................................................................................................................................................. 25 no change 

Codeine methylbromide ........................................................................................................................................... 30 no change 

Codeine-N-oxide ...................................................................................................................................................... 192 no change 

Crotonyl Fentanyl ..................................................................................................................................................... 25 no change 

Cyclopentyl Fentanyl ............................................................................................................................................... 30 no change 

Cyclopropyl Fentanyl ............................................................................................................................................... 20 no change 

Cyprenorphine ......................................................................................................................................................... 25 no change 

d-9-THC ................................................................................................................................................................... 1,523,040 no change 

Desomorphine .......................................................................................................................................................... 25 no change 

Dextromoramide ...................................................................................................................................................... 25 no change 

Diapromide ............................................................................................................................................................... 20 no change 

Diethylthiambutene .................................................................................................................................................. 20 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 78769 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

Diethyltryptamine ..................................................................................................................................................... 25 no change 

Difenoxin .................................................................................................................................................................. 9,300 no change 

Dihydromorphine ...................................................................................................................................................... 639,954 no change 

Dimenoxadol ............................................................................................................................................................ 25 no change 

Dimepheptanol ......................................................................................................................................................... 25 no change 

Dimethylthiambutene ............................................................................................................................................... 20 no change 

Dimethyltryptamine .................................................................................................................................................. 11,000 no change 

Dioxyaphetyl butyrate .............................................................................................................................................. 25 no change 

Dipipanone ............................................................................................................................................................... 25 no change 

Drotebanol ............................................................................................................................................................... 25 no change 

Ethylmethylthiambutene ........................................................................................................................................... 25 no change 

Ethylone ................................................................................................................................................................... 25 no change 

Etodesnitazene ........................................................................................................................................................ 30 no change 

Etonitazene .............................................................................................................................................................. 25 no change 

Etorphine .................................................................................................................................................................. 30 no change 

Etoxeridine ............................................................................................................................................................... 25 no change 

Eutylone ................................................................................................................................................................... 30 no change 

Fenethylline .............................................................................................................................................................. 30 no change 

Fentanyl carbamate ................................................................................................................................................. 30 no change 

Fentanyl related substances .................................................................................................................................... 600 no change 

Flunitazene .............................................................................................................................................................. 30 no change 

FUB-144 ................................................................................................................................................................... 25 no change 

FUB-AKB48 ............................................................................................................................................................. 25 no change 

Fub-AMB, MMB-Fubinaca, AMB-Fubinaca ............................................................................................................. 25 no change 

Furanyl fentanyl ....................................................................................................................................................... 30 no change 

Furethidine ............................................................................................................................................................... 25 no change 

gamma-Hydroxybutyric acid .................................................................................................................................... 29,417,000 no change 

Heroin ...................................................................................................................................................................... 150 no change 

Hydromorphinol ........................................................................................................................................................ 40 no change 

Hydroxypethidine ..................................................................................................................................................... 25 no change 

Ibogaine ................................................................................................................................................................... 150 no change 

Isobutyryl Fentanyl ................................................................................................................................................... 25 no change 

Isotonitazine ............................................................................................................................................................. 25 no change 

JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) .......................................................................................... 35 no change 

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ............................................................................................................... 45 no change 

JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ................................................................................................................ 45 no change 

JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) ........................................................................................... 30 no change 

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ............................................................................................... 30 no change 

JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ................................................................................... 35 no change 

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ................................................................................................ 30 no change 

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ............................................................................................ 30 no change 

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ................................................................................................ 30 no change 

Ketobemidone .......................................................................................................................................................... 30 no change 

Levomoramide ......................................................................................................................................................... 25 no change 

Levophenyacylmorphan ........................................................................................................................................... 25 no change 

Lysergic acid diethylamide (LSD) ............................................................................................................................ 1,200 no change 

MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ............................................................................................................................................. 30 no change 

MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3- 

dimethylbutanoate) ............................................................................................................................................... 30 no change 

MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ............... 30 no change 

MMB-CHMICA-(AMB-CHIMCA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate .. 25 no change 

Marijuana ................................................................................................................................................................. 6,675,000 no change 

Marijuana extract ..................................................................................................................................................... 1,000,000 no change 

Mecloqualone ........................................................................................................................................................... 30 no change 

Mescaline ................................................................................................................................................................. 1,200 no change 

Mesocarb ................................................................................................................................................................. 30 no change 

Methaqualone .......................................................................................................................................................... 60 no change 

Methcathinone ......................................................................................................................................................... 25 no change 

Methiopropamine ..................................................................................................................................................... 30 no change 

Methoxetamine ........................................................................................................................................................ 30 no change 

Methoxyacetyl fentanyl ............................................................................................................................................ 30 no change 

Methyldesorphine ..................................................................................................................................................... 5 no change 

Methyldihydromorphine ............................................................................................................................................ 25 no change 

Metodesnitazene ...................................................................................................................................................... 30 no change 

Metonitazene ........................................................................................................................................................... 30 no change 

Morpheridine ............................................................................................................................................................ 25 no change 

Morphine methylbromide ......................................................................................................................................... 5 no change 

Morphine methylsulfonate ........................................................................................................................................ 5 no change 

Morphine-N-oxide .................................................................................................................................................... 150 no change 

MT-45 ....................................................................................................................................................................... 30 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
78770 Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

Myrophine ................................................................................................................................................................ 25 no change 

NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate ...................................................................... 25 no change 

N,N-Dimethylamphetamine ...................................................................................................................................... 25 no change 

Naphyrone ............................................................................................................................................................... 25 no change 

N-Ethyl-1-phenylcyclohexylamine ............................................................................................................................ 25 no change 

N-Ethyl-3-piperidyl benzilate .................................................................................................................................... 10 no change 

N-Ethylamphetamine ............................................................................................................................................... 24 no change 

N-Ethylhexedrone .................................................................................................................................................... 25 no change 

N-Ethylpentylone, ephylone ..................................................................................................................................... 30 no change 

N-Hydroxy-3,4-methylenedioxyamphetamine .......................................................................................................... 24 no change 

Nicocodeine ............................................................................................................................................................. 25 no change 

Nicomorphine ........................................................................................................................................................... 25 no change 

N-methyl-3-piperidyl benzilate ................................................................................................................................. 30 no change 

N-Pyrrolidino Etonitazene ........................................................................................................................................ 30 no change 

Noracymethadol ....................................................................................................................................................... 25 no change 

Norlevorphanol ......................................................................................................................................................... 2,550 no change 

Normethadone ......................................................................................................................................................... 25 no change 

Normorphine ............................................................................................................................................................ 40 no change 

Norpipanone ............................................................................................................................................................ 25 no change 

Ocfentanil ................................................................................................................................................................. 25 no change 

ortho-Fluoroacryl fentanyl ........................................................................................................................................ 30 no change 

ortho-Fluorobutyryl fentanyl ..................................................................................................................................... 30 no change 

Ortho-Fluorofentanyl,2-Fluorofentanyl ..................................................................................................................... 30 no change 

ortho-Fluoroisobutyryl fentanyl ................................................................................................................................ 30 no change 

ortho-Methyl acetylfentanyl ...................................................................................................................................... 30 no change 

ortho-Methyl methoxyacetyl fentanyl ....................................................................................................................... 30 no change 

Para-Chlorisobutyrl fentanyl .................................................................................................................................... 30 no change 

Para-flourobutyryl fentanyl ....................................................................................................................................... 25 no change 

Para-fluorofentanyl ................................................................................................................................................... 25 no change 

para-Fluoro furanyl fentanyl ..................................................................................................................................... 30 no change 

Para-Methoxybutyrl fentanyl .................................................................................................................................... 30 no change 

Para-methoxymethamphetamine ............................................................................................................................. 30 no change 

para-Methylfentanyl ................................................................................................................................................. 30 no change 

Parahexyl ................................................................................................................................................................. 5 no change 

PB-22; QUPIC ......................................................................................................................................................... 20 no change 

Pentedrone .............................................................................................................................................................. 25 no change 

Pentylone ................................................................................................................................................................. 25 no change 

Phenadoxone ........................................................................................................................................................... 25 no change 

Phenampromide ....................................................................................................................................................... 25 no change 

Phenomorphan ........................................................................................................................................................ 25 no change 

Phenoperidine .......................................................................................................................................................... 25 no change 

Phenyl fentanyl ........................................................................................................................................................ 30 no change 

Pholcodine ............................................................................................................................................................... 5 no change 

Piritramide ................................................................................................................................................................ 25 no change 

Proheptazine ............................................................................................................................................................ 25 no change 

Properidine ............................................................................................................................................................... 25 no change 

Propiram .................................................................................................................................................................. 25 no change 

Protonitazene ........................................................................................................................................................... 30 no change 

Psilocybin ................................................................................................................................................................. 20,000 30,000 

Psilocyn .................................................................................................................................................................... 24,000 36,000 

Racemoramide ......................................................................................................................................................... 25 no change 

SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ............................................................... 45 no change 

SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) .................................................................................. 30 no change 

Tetrahydrofuranyl fentanyl ....................................................................................................................................... 15 no change 

Thebacon ................................................................................................................................................................. 25 no change 

Thiafentanil .............................................................................................................................................................. 25 no change 

Thiofentanyl ............................................................................................................................................................. 25 no change 

Thiofuranyl fentanyl ................................................................................................................................................. 30 no change 

THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .......................................................... 30 no change 

Tilidine ...................................................................................................................................................................... 25 no change 

Trimeperidine ........................................................................................................................................................... 25 no change 

UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .......................................................... 25 no change 

U-47700 ................................................................................................................................................................... 30 no change 

Valeryl fentanyl ........................................................................................................................................................ 25 no change 

Zipeprol .................................................................................................................................................................... 30 no change 

Schedule II 

1-Phenylcyclohexylamine ........................................................................................................................................ 15 no change 

1-Piperidinocyclohexanecarbonitrile ........................................................................................................................ 25 no change 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................. 937,874 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 78771 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

Alfentanil .................................................................................................................................................................. 5,000 no change 

Alphaprodine ............................................................................................................................................................ 25 no change 

Amobarbital .............................................................................................................................................................. 20,100 no change 

Bezitramide .............................................................................................................................................................. 25 no change 

Carfentanil ................................................................................................................................................................ 20 no change 

Cocaine .................................................................................................................................................................... 60,492 no change 

Codeine (for conversion) ......................................................................................................................................... 942,452 no change 

Codeine (for sale) .................................................................................................................................................... 19,262,957 no change 

d-amphetamine (for sale) ........................................................................................................................................ 21,200,000 no change 

d,l-amphetamine ...................................................................................................................................................... 21,200,000 no change 

d-amphetamine (for conversion) .............................................................................................................................. 23,688,235 no change 

Dexmethylphenidate (for sale) ................................................................................................................................. 6,200,000 no change 

Dexmethylphenidate (for conversion) ...................................................................................................................... 5,374,683 no change 

Dextropropoxyphene ................................................................................................................................................ 35 no change 

Dihydrocodeine ........................................................................................................................................................ 115,227 no change 

Dihydroetorphine ...................................................................................................................................................... 25 no change 

Diphenoxylate (for conversion) ................................................................................................................................ 14,100 no change 

Diphenoxylate (for sale) ........................................................................................................................................... 770,800 no change 

Ecgonine .................................................................................................................................................................. 60,492 no change 

Ethylmorphine .......................................................................................................................................................... 30 no change 

Etorphine hydrochloride ........................................................................................................................................... 32 no change 

Fentanyl ................................................................................................................................................................... 731,360 731,341 

Glutethimide ............................................................................................................................................................. 25 no change 

Hydrocodone (for conversion) ................................................................................................................................. 1,250 no change 

Hydrocodone (for sale) ............................................................................................................................................ 27,143,545 27,121,498 

Hydromorphone ....................................................................................................................................................... 1,951,801 1,951,508 

Isomethadone .......................................................................................................................................................... 30 no change 

L-amphetamine ........................................................................................................................................................ 30 no change 

Levo-alphacetylmethadol (LAAM) ............................................................................................................................ 25 no change 

Levomethorphan ...................................................................................................................................................... 30 no change 

Levorphanol ............................................................................................................................................................. 20,000 no change 

Lisdexamfetamine .................................................................................................................................................... 32,736,000 no change 

Meperidine ............................................................................................................................................................... 681,184 no change 

Meperidine Intermediate-A ...................................................................................................................................... 30 no change 

Meperidine Intermediate-B ...................................................................................................................................... 30 no change 

Meperidine Intermediate-C ...................................................................................................................................... 30 no change 

Metazocine ............................................................................................................................................................... 15 no change 

Methadone (for sale) ............................................................................................................................................... 25,619,700 no change 

Methadone Intermediate .......................................................................................................................................... 27,673,600 no change 

d,l-Methamphetamine .............................................................................................................................................. 150 no change 

d-methamphetamine (for conversion) ...................................................................................................................... 485,020 no change 

d-methamphetamine (for sale) ................................................................................................................................ 47,000 no change 

l-methamphetamine ................................................................................................................................................. 587,229 no change 

Methylphenidate (for sale) ....................................................................................................................................... 53,283,000 no change 

Methylphenidate (for conversion) ............................................................................................................................ 19,975,468 no change 

Metopon ................................................................................................................................................................... 25 no change 

Moramide-intermediate ............................................................................................................................................ 25 no change 

Morphine (for conversion) ........................................................................................................................................ 2,393,200 no change 

Morphine (for sale) .................................................................................................................................................. 20,805,957 no change 

Nabilone ................................................................................................................................................................... 62,000 no change 

Norfentanyl ............................................................................................................................................................... 25 no change 

Noroxymorphone (for conversion) ........................................................................................................................... 22,044,741 24,756,979 

Noroxymorphone (for sale) ...................................................................................................................................... 1,000 no change 

Oliceridine ................................................................................................................................................................ 25,100 no change 

Opium (powder) ....................................................................................................................................................... 250,000 no change 

Opium (tincture) ....................................................................................................................................................... 530,837 no change 

Oripavine .................................................................................................................................................................. 33,010,750 37,721,950 

Oxycodone (for conversion) .................................................................................................................................... 437,827 no change 

Oxycodone (for sale) ............................................................................................................................................... 53,658,226 53,584,449 

Oxymorphone (for conversion) ................................................................................................................................ 28,204,371 31,773,105 

Oxymorphone (for sale) ........................................................................................................................................... 464,464 no change 

Pentobarbital ............................................................................................................................................................ 40,000,000 no change 

Phenazocine ............................................................................................................................................................ 25 no change 

Phencyclidine ........................................................................................................................................................... 35 no change 

Phenmetrazine ......................................................................................................................................................... 25 no change 

Phenylacetone ......................................................................................................................................................... 100 no change 

Piminodine ............................................................................................................................................................... 25 no change 

Racemethorphan ..................................................................................................................................................... 5 no change 

Racemorphan .......................................................................................................................................................... 5 no change 

Remifentanil ............................................................................................................................................................. 3,000 no change 

Secobarbital ............................................................................................................................................................. 172,100 no change 


ddrumheller on DSK120RN23PROD with NOTICES7
78772 Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices 

15 21 CFR 1303.13(c) and 1315.13(c). 

Basic class 

Established 

2024 quotas 

(g) 

Proposed 

revised 2024 

quotas 

(g) 

Sufentanil ................................................................................................................................................................. 4,000 no change 

Tapentadol ............................................................................................................................................................... 10,390,226 no change 

Thebaine .................................................................................................................................................................. 57,137,944 no change 

List I Chemicals 

Ephedrine (for conversion) ...................................................................................................................................... 41,100 no change 

Ephedrine (for sale) ................................................................................................................................................. 3,933,336 no change 

Phenylpropanolamine (for conversion) .................................................................................................................... 14,878,320 no change 

Phenylpropanolamine (for sale) ............................................................................................................................... 7,990,000 no change 

Pseudoephedrine (for conversion) .......................................................................................................................... 1,000 no change 

Pseudoephedrine (for sale) ..................................................................................................................................... 186,617,466 no change 

The Administrator further proposes 

that the APQ for all other schedule I and 

II controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. In accordance with 21 CFR 

1303.13 and 21 CFR 1315.13, upon 

consideration of the relevant factors, the 

Administrator may adjust the 2024 APQ 

and AAN as needed. 

Conclusion 

After consideration of any comments 

or objections, or after a hearing, if one 

is held, the Administrator will issue and 

publish in the Federal Register a final 

order establishing any adjustment of the 

2024 APQ for each basic class of 

controlled substances in schedules I and 

II and AAN for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine.15

Signing Authority 

This document of the Drug 

Enforcement Administration was signed 

on September 20, 2024, by 

Administrator Anne Milgram. That 

document with the original signature 

and date is maintained by DEA. For 

administrative purposes only, and in 

compliance with requirements of the 

Office of the Federal Register, the 

undersigned DEA Federal Register 

Liaison Officer has been authorized to 

sign and submit the document in 

electronic format for publication, as an 

official document of DEA. This 

administrative process in no way alters 

the legal effect of this document upon 

publication in the Federal Register. 

Heather Achbach, 

Federal Register Liaison Officer, Drug 

Enforcement Administration. 

[FR Doc. 2024–21960 Filed 9–20–24; 4:15 pm] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1413P] 

Proposed Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2025 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration (DEA) proposes to 

establish the 2025 aggregate production 

quotas for controlled substances in 

schedules I and II of the Controlled 

Substances Act (CSA) and the 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.11(c) and 

1315.11(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before 

October 25, 2024. Commenters should 

be aware that the electronic Federal 

Docket Management System will not 

accept comments after 11:59 p.m. 

Eastern Time on the last day of the 

comment period. 

Based on comments received in 

response to this notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

her sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the 

Administrator will publish in the 

Federal Register a final order 

establishing the 2025 aggregate 

production quotas for schedule I and II 

controlled substances, and an 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–1413P’’ on all correspondence, 

including any attachments. DEA 

encourages that all comments be 

submitted electronically through the 

Federal eRulemaking Portal, which 

provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to http:// 

www.regulations.gov and follow the 

online instructions at that site for 

submitting comments. Upon completion 

of your submission, you will receive a 

Comment Tracking Number for your 

comment. 

Please be aware that submitted 

comments are not instantaneously 

available for public view on 

Regulations.gov. If you have received a 

Comment Tracking Number, your 

comment has been successfully 

submitted, and there is no need to 

resubmit the same comment. Paper 

comments that duplicate electronic 

submissions are not necessary and are 

discouraged. Should you wish to mail a 

paper comment in lieu of an electronic 

comment, it should be sent via regular 

or express mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Heather E. Achbach, Regulatory Drafting 

and Policy Support Section, Diversion 

Control Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (571) 776–3882. 


ddrumheller on DSK120RN23PROD with NOTICES7